HC Wainwright & Co. Reiterates Buy on Outlook Therapeutics, Maintains $30 Price Target

Benzinga · 01/17 12:31
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $30 price target.